EMA Wants Stakeholder Input On Regulatory Challenges To 2025
The EMA has launched a six-month consultation on the challenges facing the agency and the wider EU regulatory network in the face of emerging scientific and technological advances, and has put forward a range of recommendations for action in the period to 2025 to ensure the regulatory system is fit for purpose.
You may also be interested in...
The European Medicines Agency has identified key areas where stakeholders want to see it deliver a real change over the next five years.
Drug review times in the EU are not getting slower but other agencies are getting faster. A pharmaceutical industry representative offers some frank advice on how the EU can stay competitive.
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.